100,825 Shares in Kenvue Inc. $KVUE Purchased by Arlington Partners LLC

Key Points

• Arlington Partners LLC acquired 100,825 shares of Kenvue Inc., valued at approximately $2.11 million, according to a recent SEC filing.
• Kenvue's quarterly earnings report revealed an EPS of $0.29, exceeding analyst expectations, but with revenue down 4.0% year-over-year.
• The company recently increased its quarterly dividend to $0.2075 per share, representing a yield of 4.5%.

Arlington Partners LLC bought a new position in Kenvue Inc. (NYSE:KVUE - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 100,825 shares of the company's stock, valued at approximately $2,110,000.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company's stock worth $5,494,882,000 after purchasing an additional 10,600,682 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Kenvue by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company's stock worth $613,882,000 after purchasing an additional 633,461 shares during the period. Boston Partners raised its holdings in Kenvue by 7.4% in the first quarter. Boston Partners now owns 25,346,453 shares of the company's stock worth $606,920,000 after purchasing an additional 1,750,490 shares during the period. JPMorgan Chase & Co. raised its holdings in Kenvue by 11.6% in the first quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company's stock worth $597,395,000 after purchasing an additional 2,597,920 shares during the period. Finally, American Century Companies Inc. raised its holdings in shares of Kenvue by 15.7% during the first quarter. American Century Companies Inc. now owns 21,828,854 shares of the company's stock worth $523,456,000 after acquiring an additional 2,961,716 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on KVUE. JPMorgan Chase & Co. dropped their price objective on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a report on Friday, July 25th. Evercore ISI dropped their price objective on shares of Kenvue from $25.00 to $23.00 and set an "in-line" rating on the stock in a report on Monday, September 8th. Citigroup dropped their price objective on shares of Kenvue from $22.00 to $20.00 and set a "neutral" rating on the stock in a report on Tuesday, September 16th. Zacks Research upgraded shares of Kenvue to a "strong sell" rating in a report on Monday, August 11th. Finally, Royal Bank Of Canada dropped their price objective on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a report on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Kenvue has a consensus rating of "Hold" and an average target price of $24.04.

Kenvue Stock Performance

Shares of KVUE traded down $1.38 during midday trading on Monday, reaching $16.96. The stock had a trading volume of 74,831,635 shares, compared to its average volume of 27,946,758. The firm has a 50 day simple moving average of $20.77 and a 200-day simple moving average of $22.00. Kenvue Inc. has a one year low of $16.89 and a one year high of $25.17. The firm has a market cap of $32.55 billion, a PE ratio of 22.92, a P/E/G ratio of 2.63 and a beta of 0.83. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter last year, the firm posted $0.32 EPS. The company's quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a $0.2075 dividend. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.9%. Kenvue's payout ratio is 112.16%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.